Healing & recovery · Evidence comparison

BPC-157 vs TB-500

The two peptides most often stacked for injury recovery. Neither is FDA-approved for people — but their evidence isn't equal, and both are widely mis-sold.

BPC-157

AAccelerates healing of tendon, ligament, muscle, and bone injuries
vs

TB-500

BAccelerates muscle, tendon, and ligament healing (the use it's sold for)

Headline claim shown. Grades are claim-specific — see the full breakdown below.

The evidence, side by side

Every graded claim from each brief. Grades are read straight from the source-checked briefs — one molecule can be strong for one use and weak for another.

Healing / recovery

BPC-157

Evidence grades

A
Accelerates healing of tendon, ligament, muscle, and bone injuriesMostly preclinical
A
Protects and heals the gastrointestinal tractMostly preclinical
B
Relieves knee / joint pain in humansMostly anecdotal
B
Is a proven, safe all-purpose recovery aid for peopleMostly anecdotal

Healing / recovery

TB-500

Evidence grades

B
Accelerates muscle, tendon, and ligament healing (the use it's sold for)Mostly anecdotal
S
Full-length thymosin beta-4 (NOT TB-500) aids corneal / ocular wound healingLimited human evidence
C
Is a proven injectable recovery aid for peopleUnsupported

Regulatory status at a glance

BPC-157

Not FDA-approved for human use. Removed from FDA compounding 'Category 2' in April 2026 after nominations were withdrawn — a procedural change that does NOT by itself authorize compounding. A July 2026 FDA advisory committee will consider adding it to the 503A bulks list. Banned in sport by WADA (class S0) since 2022 and on the U.S. DoD prohibited list. Currently sold gray-market as 'research only.'

TB-500

Not FDA-approved for human use. Listed by the FDA as 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; removed from compounding 'Category 2' in April 2026 after nominations were withdrawn — which does NOT by itself authorize compounding. On the July 2026 FDA advisory committee agenda. Prohibited at all times in sport by WADA. Currently sold gray-market as 'research only.'

Key differences

  • BPC-157's injury-healing claim is graded A (mostly animal/preclinical); TB-500's marketed recovery claim is graded B (mostly anecdotal).
  • TB-500 is a fragment — the real human research is on the full-length protein thymosin beta-4 (graded S for corneal/ocular healing), not the fragment being sold.
  • Neither has controlled human trials for the muscle and tendon uses they're marketed for, and both are graded down accordingly.
  • Both are not FDA-approved, banned by WADA, and sold gray-market as 'research only.'

The bottom line

BPC-157 has more (animal) evidence behind its healing claim than TB-500 has behind its marketed use, but neither clears the bar of human proof — and TB-500's strongest human data belongs to a different molecule entirely. We don't recommend using either; we show exactly how thin the human evidence is for both.

PeptideIQ Base does not recommend, rank, or endorse any peptide, dose, or product. We grade the strength of the evidence so you can read it for yourself.

Read the full briefs

Full evidence brief

BPC-157 →

A synthetic 15-amino-acid peptide, derived from a protein in human gastric juice, that is widely promoted for injury and gut healing but whose evidence is almost entirely from animal studies.

Full evidence brief

TB-500 →

A synthetic 7-amino-acid fragment of the natural protein thymosin beta-4, sold for injury recovery — but the real human research is on the full protein, not this fragment.

See every peptide, graded on one page

The Peptide Evidence Report Card grades all our peptides S+ to C on the strength of the human evidence. Research only — no hype, never a recommendation.

Get the report card →

More comparisons

BPC-157 vs GHK-CuTB-500 vs GHK-CuAll comparisons →